Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Market Cap	4.89M 4.26M 4.02M 3.65M 6.84M 469M 6.87M 48.18M 18.59M 238M 18.35M 17.94M 767M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.16M 10.54M 9.57M 17.93M 1.23B 18M 126M 48.71M 624M 48.08M 47.01M 2.01B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
20-04-27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
20-04-08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
20-03-30	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
20-03-30	Motion for Asset Sale Approved for Aradigm Corporation	CI
20-03-09	Bidding Procedure Approved for Aradigm Corporation	CI
20-02-20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20-02-20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
19-10-30	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
19-10-21	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19-07-19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

20-06-15	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-04	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-04-13	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Aradigm Corporation Stock

Stocks

ARDMQ

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news: Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	+6.73%	-	-	702K
LONZA GROUP AG	+0.11%	+2.71%	+0.33%	+28.59%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+40.07%	+27.26%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+322.27%	+517.36%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+2.32%	+67.94%	39.9B
CELLTRION, INC.	-0.50%	+0.67%	+11.79%	+40.51%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+21.99%	+124.21%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.15%	+38.93%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-10.60%	-	14.05B
Average	-0.89%	+4.06%	+51.29%	+120.69%	26.24B
Weighted average by Cap.	-1.02%	+1.87%	+64.69%	+130.23%

	2016	2017
Net sales	195K 170K 161K 146K 273K 18.71M 274K 1.92M 742K 9.51M 733K 716K 30.61M	14.46M 12.61M 11.91M 10.82M 20.26M 1.39B 20.35M 143M 55.05M 706M 54.34M 53.13M 2.27B
Net income	-32.94M -28.72M -27.12M -24.63M -46.14M -3.16B -46.33M -325M -125M -1.61B -124M -121M -5.17B	-10.7M -9.33M -8.81M -8M -15M -1.03B -15.06M -106M -40.74M -522M -40.21M -39.32M -1.68B
Net Debt	-9.37M -8.17M -7.72M -7.01M -13.13M -899M -13.18M -92.43M -35.67M -457M -35.21M -34.42M -1.47B	7.91M 6.9M 6.52M 5.92M 11.08M 759M 11.13M 78.04M 30.12M 386M 29.73M 29.07M 1.24B